Introduction
Human papillomavirus (HPV) plays a central etiologic role in an expanding subset of head and neck cancer (HNC) patients (1, 2) . Clinical reports provide clear evidence of improved outcome in patients with HPV-positive (HPV+) HNC versus HPVnegative (HPV-) tumors (3, 4) . This result that has been postulated to reflect increased radiation sensitivity in HPV+ tumors (5) . However, published results for the few HPV+ cancer cell lines investigated to date are conflicting with some data suggesting enhanced sensitivity to radiation and some suggesting reduced sensitivity or no effect (6) (7) (8) (9) . The strength of these data are somewhat limited due to the model systems used: p53 mutated cells, non-head and neck cancer cell lines, and absence of rigorous validation of HPV status. Clarification of this discrepancy is important to clinical investigators as they consider future clinical trials that incorporate radiation dose reduction and seek underlying mechanisms to explain the markedly improved survival outcomes observed in patients with HPV+ HNC.
The classical HPV-HNC, related to more traditional risk factors such as tobacco and/or alcohol exposure, is driven by a series of mutations in tumor suppressor genes and proto-oncogenes. While many of these mutations occur randomly, recent nextgeneration sequencing approaches have identified mutations in common genes or their resultant protein pathways including TP53, NOTCH, PIK3CA, and CDKN2A (10) (11) (12) . In fact, it is estimated that approximately 80% of HPV-negative (HPV-) HNCs harbor mutations in TP53 resulting in impaired or absent function of its encoded protein p53 (10) (11) (12) . Author Manuscript Published OnlineFirst on June 7, 2013; DOI: 10.1158/0008-5472. Alternatively, during the development of HPV+ HNC, an initial viral infection results in expression of virally encoded oncogenes that can have dramatic effects on normal host cellular function. Canonically, the HPV proteins E6 and E7 down regulate the tumor suppressor proteins p53 and Rb, respectively, although their true interactome encompasses a wide variety of cellular targets (13) . Recent work has shown that the E6 and E7 proteins act synergistically to induce HNC in a transgenic mouse model system and that additional targets (e.g. p107 and p130) besides Rb are targeted by E7 (14) (15) (16) .
This coordinated perturbation of two critical tumor suppressor pathways results in uncontrolled growth and proliferation although with a mutational landscape that is significantly restricted when compared to HPV-HNC (10) (11) (12) .
Standard therapy for patients with locally advanced HNC commonly involves the combination of radiation and cisplatin chemotherapy. Surgery is often incorporated either in the initial management or as salvage following definitive radiochemotherapy (reviewed in (17) ). In 2013, despite the significant differences in underlying biology and ultimate outcome, there are no validated differences in treatment approach based on HPV status, beyond the context of clinical trials. In addition, there is little preclinical data to support a given treatment approach owing, at least in part, to the lack of preclinical model systems of HPV+ HNC.
During the last two years, we have systematically investigated the therapeutic sensitivity of a panel of validated HPV+ and HPV-HNC cell lines, in an effort to generate preclinical data to support etiology-specific treatment approaches. As identified, we sought to further investigate mechanisms underlying these altered responses and to validate the findings in an in vivo model system.
Methods
Cell lines and culture conditions. Head and neck cancer lines derived from HPVpatients: UM-SCC1, UM-SCC6, UM-SCC22B, and SCC-1483 and from HPV+ patients:
UD-SCC2, UM-SCC47, UPCI-SCC90, and 93-VU-147T were obtained from indicated sources (Supplemental Table 1 ). Standard culture conditions were used (Supplemental Table 1 ). The identity of all cell lines was confirmed via short tandem repeat testing within 6 months of cell use.
Immortalized human tonsillar epithelial (HTE) cells were generated by cotransduction of primary HTE cells with a pBABE-Hygro-TERT retroviral vector (a gift from Dr. Robert Weinberg) and a shRNA-p16-Puro-MSCV retroviral vector (a gift from Dr. Scott Lowe) using transduction techniques as previously described (18) . HTE cells stably carrying LXSN vector alone, or engineered to encode HPV16 E6, E7 or E6 and E7 were cultured in keratinocyte serum free media (Cat # 17005042, Invitrogen, Carlsbad, CA) supplemented with 0.16 ng/ml EGF and 25 µg/ml Bovine Pituitary Extract at 37ºC in a humidified atmosphere of 5% C0 2 .
Validation of HPV -Southern blot was performed using 10 µg of BamHI digested total cellular DNA. DNA was separated on a 1.25% agarose gel, transferred to Hybond N+ nylon membrane (Amersham, Pittsburgh, PA) and crosslinked. DNA probes were made by 5' end labeling 10 pmoles of HPV16 specific oligonucleotides (Supplemental Table 2 P] ATP (6,000 Ci/mmol) at 37°C for 1.5 hours. The membrane was pre-hybridized with Church hybridization buffer for 15 minutes at 52°C followed by probe hybridization for 18 hours at 52°C in a hybridization oven. Membrane was washed with Church wash buffer, exposed to a storage phosphor screen and scanned using a Typhoon 8610 imaging system (Amersham).
Quantitative reverse-transcriptase PCR (qRT-PCR) was performed to confirm transcription of HPV-16 E5, E6, and E7 on a BioRad CFX96 using primers and probes (Supplemental Table 2 ) purchased from Integrated DNA Technologies, Inc. (Coralville, IA). Briefly, total RNA was harvested using the miRNeasy with RNeasy MinElute Cleanup Kit (Cat# 217004 and 74204, Qiagen, Valencia, CA) from confluent plates of both HPV+ and HPV-cell lines. cDNA was synthesized using the iScript Reverse Transcription Supermix kit (Bio-Rad Laboratories, Hercules, CA) and 1,000 ng of total RNA. qRT-PCR was performed by using IQ Multiplex Powermix with 10 ng cDNA per 10 μl reaction. GAPDH, HPV-16 E5, E6, E7 and TP53 transcripts were detected using primers and probes (Supplemental Table 2 ) purchased from Integrated DNA Technologies, Inc. (Coralville, IA). The thermocycler was programmed for an initial 95°C for 7 minutes followed by 40 cycles of 94°C for 15 seconds and 60°C for 30 seconds.
Clonogenic survival assays.
Clonal survival of cells following radiation was performed as previously described using a JL Shepherd 137 Cs irradiator (JL Shepherd, San Fernando, CA) delivering a dose rate of approximately 400 cGy/min (19) . After 10 to 15 days, colonies containing more than 50 cells were counted, the surviving fraction calculated, and clonogenic survival curves fit to a linear-quadratic model, as previously described (19) . Clonogenic survival curves were compared using the extra sum-of- and E7 (+16E6E7) were used to perform colony formation assays. A decrease in clonogenic survival (corresponding to increased sensitivity to radiation) was seen in both 16E6 and 16E6E7 expressing cells ( Figure 4C ). Interestingly, little increase in the G2 fraction was seen in HTE-16E6 cells while expression of both E6 and E7 resulted in a significant G2 arrest ( Figure 4D) 
E6 and E6/E7 resulted in an increase in apoptosis as measured by caspase activity ( Figure 4E ).
Knockdown of TP53 results in radiation resistance -We hypothesized that the wild type TP53 present in the +16E6 and +16E6E7 cells was being reactivated following radiation resulting in improved sensitivity to radiation. To test this hypothesis we performed siRNA-mediated knockdown of p53 in our HTE +16E6 cell line in addition to using two HPV+ HNC cell lines. As expected, compared to vector alone, expression of 16E6 resulted in a decrease in detectable p53 ( Figure 5A ). Use of aTP53 specific siRNA, but not vehicle or scrambled control siRNA, led to a further reduction in p53 expression to levels that were undetectable ( Figure 5A ). Similar decreases in total p53
were seen in 93-VU-147T and UM-SCC47 cells treated with the same siRNA, but not with scrambled control siRNA (data not shown). Using clonogenic survival assays, treatment with scrambled siRNA resulted in a survival fraction similar to that previously seen in untreated cells ( Figure 1C and 4C) . Use of TP53 specific siRNA resulted in a significant increase in colony formation consistent with radiation resistance in HTE +16E6, UM-SCC47, and 93-VU-147T cells ( Figure 5B ).
In vivo radiation sensitivity -To determine whether the increased radiation sensitivity seen in vitro was also present in vivo, we utilized a cell line xenograft system. All four HPV+ cell lines ( Figure 6A ) and all 4 HPV-cell lines (data not shown) were grown as flank-implanted xenografts. An initial dose-finding experiment was performed with UM-SCC47 and a dose/fractionation schedule of 2 Gy delivered twice weekly to a total dose of 8 Gy was adopted for all subsequent experiments. Even this relatively low radiation dose resulted in significant tumor growth delay in 3 of 4 HPV+ cell lines ( Figure 6A ). 
However, the relatively rapid tumor growth rate, coupled with the prolonged time interval between radiation fractions, elicited no overall tumor regression in these xenografts.
When a higher daily dose (4 Gy per fraction) was utilized in the UM-SCC47 cell line, modest tumor regression was seen (data not shown). Interestingly, the slowest growing line, 93-VU-147T, demonstrated modest tumor regression in the irradiated tumors, but overall tumor growth was not significantly different after 100 days.
To determine whether a significant difference in populations was seen, time to tumor quadrupling from the first day of treatment was calculated for all eight xenografts. Using these well-validated clonal HPV+ HNC cell lines, we demonstrate that they are consistently more sensitive to radiation than HPV-HNC cells both in vitro and in vivo. As expected, there is considerable variation in radiation sensitivity in both HPV+ and HPV-cells. This is certainly true in the clinical domain where HNC patients exhibit a broad spectrum of response to radiation, and we would therefore anticipate a broad response heterogeneity in the preclinical setting as well. Nevertheless, our systematic We propose a model (Figure 7 ) in which titration of the levels of p53 expression plays a critical role in regulating therapeutic response. In the development of HPV-HNC, TP53 or members of its pathway are commonly mutated, preventing a normal response to radiation induced DNA damage. However, in HPV+ HNC, the HPV-16 E6 oncoprotein induces degradation of p53, an effect that plays a critical role in the induction of cancer but that also removes selective pressure to develop mutations in TP53 or p53-response pathways. Our data suggests that low levels of wild type, normally functioning, p53 remain in HPV+ cell lines despite the downregulating effects of E6, and that this p53 can be activated by therapeutic stress such as radiation. This apparently protective response of p53 can be overcome by more complete knockdown of p53 by siRNA. We believe that this response results in prolonged G2 arrest, a result likely augmented by the known additional effects of HPV E6 and E7 to bypass G1 checkpoint control (reviewed in (29)). Finally, perhaps due to a failure of HPV+ cells to repair DNA damage, cells eventually undergo cell death by apoptosis. Several additional studies have investigated the effects of HPV proteins on radiation sensitivity outside of the head and neck. DeWeese and colleagues showed no effect of E6 or E7 on radiation sensitivity in a study using human colon cancer cell lines We acknowledge several limitations of our work. Importantly, the in vivo work has been performed using mice with a compromised immune system. Thus, differences observed in radiosensitivity in vitro and in vivo in our study reflect the inherent radiation sensitivity difference between HPV+ and HPV-HNC cells that is not dependent upon immune surveillance. Spanos and colleagues have suggested that tumor control of mouse tonsillar epithelial cells expressing the human HPV16 E6 and E7 proteins is improved in an immunocompetent mouse compared to a RAG knockout mouse with a compromised immune system (7) . It may well be that the presence of a robust immune response further increases tumor control of HPV+ HNC thus magnifying differences in intrinsic radiation sensitivity. However, the consistent findings from both in vitro clonogenic survival assays and in vivo tumor growth delay assays provide support to our conclusions that would not be possible with only one of the chosen systems. In addition, while there are now thousands of HPV+ HNC patients and biopsy specimens available, there are only a handful of documented HPV+ HNC cell lines available worldwide. We solicited and studied all available cell lines when we commenced this study, but the scarcity of established HPV+ tumor cell lines raises an important question as to why it has been so challenging to isolate and propogate HNC cell lines from 
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